As of November 6, 2026, Kailera Therapeutics, Inc. is a publicly traded company (Nasdaq: KLRA). The largest holder reporting an active stake on Schedule 13D is BCPE Perseus Investor, LP, at 20.27%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D, April 23, 2026).
Is this your company?
About to sign with, pay or invest in Kailera Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Kailera Therapeutics, Inc. a real, registered company?
- Kailera Therapeutics, Inc. files with the SEC under CIK 2096997 (its SEC filings).
- Its shares are listed under the ticker KLRA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Waltham, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Kailera Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RTW Investments (filed 2026-08-14).
Who are Kailera Therapeutics, Inc.'s owners and officers?
Kailera Therapeutics, Inc.: incorporated in Delaware; business address in Waltham, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-14 | Rtw Investments, LP | 8.3% |
| Schedule 13G, 2026-08-14 | Cpp Investment Board Private Holdings (4) Inc. | 5.6% |
| Schedule 13G, 2026-08-05 | Jiangsu Hengrui Pharmaceuticals Co., LTD. | 8.9% |
| Schedule 13D, 2026-04-23 | Bcpe Perseus Investor, LP | 20.27% |
| Schedule 13D, 2026-04-23 | Bcls Fund Iv Investments, L.P. | 17.43% |
Questions about who owns Kailera Therapeutics, Inc.
Who owns Kailera Therapeutics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Kailera Therapeutics, Inc.: Bcpe Perseus Investor, LP (20.27%, Schedule 13D, filed 2026-04-23), Bcls Fund Iv Investments, L.P. (17.43%, Schedule 13D, filed 2026-04-23), Jiangsu Hengrui Pharmaceuticals Co., LTD. (8.9%, Schedule 13G, filed 2026-08-05), Rtw Investments, LP (8.3%, Schedule 13G, filed 2026-08-14) and Cpp Investment Board Private Holdings (4) Inc. (5.6%, Schedule 13G, filed 2026-08-14).
Who are the largest shareholders of Kailera Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Kailera Therapeutics, Inc. on this page are Bcpe Perseus Investor, LP (20.27%), Bcls Fund Iv Investments, L.P. (17.43%) and Jiangsu Hengrui Pharmaceuticals Co., LTD. (8.9%).
When did Bcpe Perseus Investor, LP buy into Kailera Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Bcpe Perseus Investor, LP on this page is the Schedule 13D, filed 2026-04-23, reporting 20.27%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Kailera Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Kailera Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Kailera Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Kailera Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Bain Capital XIV General Partner, LLC, a 10% owner: 26,255,581 shares (20.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-20).
- BCPE Perseus Investor GP, LLC, a 10% owner: 26,255,581 shares (20.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-20).
- , LP, a 10% owner: 26,255,581 shares (20.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-20).
- Bain Capital Fund XIV, L.P., a 10% owner: 26,255,581 shares (20.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-20).
- Bain Capital Investors LLC, a 10% owner: 26,255,581 shares (20.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-04-20).
Shares outstanding: 129,850,481 as of 2026-10-29, from the company's latest SEC cover page.
How much has Kailera Therapeutics, Inc. raised?
Latest IPO step: Kailera Therapeutics, Inc. filed its final IPO prospectus, ticker KLRA (424B4, 2026-04-17).
IPO filings: 424B4, 2026-04-17, S-1/A, 2026-04-13, S-1, 2026-03-27; ticker KLRA on Nasdaq Global Select Market.
Keep reading
More on Kailera Therapeutics, Inc. and the records around it.
Kailera Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. also filed stake reports on 1 other company: Braveheart Bio, Inc. (Nov 2026)
- CPP Investment Board Private Holdings (4) Inc. also filed stake reports on 12 other companies: ReNew Energy Global plc (Oct 2026), Americold Realty Trust, Inc. (Aug 2026), Chewy, Inc. (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), ORUKA THERAPEUTICS, INC. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/kailera-therapeutics